This publication is intended to contribute to prevention and control of the morbidity and mortality associated with dengue and to serve as an authoritative reference source for health workers and researchers. These guidelines are not intended to replace national guidelines but to assist in the development of national or regional guidelines. They are expected to remain valid for five years (until 2014), although developments in research could change their validity.--Publisher's description.
This book brings together an international group of experts on dengue and related flaviviruses to examine, critically, current knowledge regarding the dengue virus, the host response and the pathogenesis of dengue haemorrhagic fever and to explore the opportunities to develop new treatments. Issues addressed include the molecular biology of the dengue virus with particular emphasis on its structure and function and on the targeting of virus proteins by potential anti-viral agents. The interaction of the dengue virus with host target cells and the specific receptors on these cells is reviewed. Finally, the book outlines the options for treatment of dengue and dengue haemorrhagic fever, paying particular attention to ways in which vector, host and environment can play a critical role in the spread of this disease. A unique feature of this series is the in-depth discussion sections at the end of each chapter: these record the questions, comments and opinions of the experts in the field concerning all areas of research into dengue viruses and potential treatments.
THE ESSENTIAL WORK IN TRAVEL MEDICINE -- NOW COMPLETELY UPDATED FOR 2018 As unprecedented numbers of travelers cross international borders each day, the need for up-to-date, practical information about the health challenges posed by travel has never been greater. For both international travelers and the health professionals who care for them, the CDC Yellow Book 2018: Health Information for International Travel is the definitive guide to staying safe and healthy anywhere in the world. The fully revised and updated 2018 edition codifies the U.S. government's most current health guidelines and information for international travelers, including pretravel vaccine recommendations, destination-specific health advice, and easy-to-reference maps, tables, and charts. The 2018 Yellow Book also addresses the needs of specific types of travelers, with dedicated sections on: · Precautions for pregnant travelers, immunocompromised travelers, and travelers with disabilities · Special considerations for newly arrived adoptees, immigrants, and refugees · Practical tips for last-minute or resource-limited travelers · Advice for air crews, humanitarian workers, missionaries, and others who provide care and support overseas Authored by a team of the world's most esteemed travel medicine experts, the Yellow Book is an essential resource for travelers -- and the clinicians overseeing their care -- at home and abroad.
Dengue virus is a member of the Flaviviridae family, which includes viruses associated with human diseases such as yellow fever, Japanese encephalitis and hepatitis C. Dengue fever is transmitted by mosquitoes, principally Aedes aegypti. There are four serotypes of dengue virus, of which DENV-2 has been the most prevalent in many recent epidemics. Following primary infection, lifelong immunity develops, preventing repeated assault by the same serotype. However, the non-neutralizing antibodies from a previous infection or maternally acquired antibodies are thought to form complexes with a different serotype during a subsequent infection and cause dengue haemorrhagic fever/dengue shock syndrome, which can be fatal. There is no treatment or vaccine available today that can combat this emerging and uncontrolled disease. This book features contributions from the world’s leading researchers working on dengue and related flaviviruses who examine the current state of the art in the molecular biology of the dengue virus. Particular emphasis is placed on the structure and function of the virus and the targeting of virus proteins by potential antiviral agents. The pathogenesis of dengue and dengue haemorrhagic fever are discussed in detail, especially the target cells and the specific receptors on these cells, thereby developing a clear overview of host and viral factors that contribute to dengue haemorrhagic fever. Finally, the book reviews the therapeutic options, paying particular attention to ways in which vector, host and environment can play a critical role in the spread of this disease. With dengue fever and other emerging viral diseases becoming increasingly prevalent around the world, this book provides valuable insight into the virus that causes this disease and potential ways to manage it. It is essential reading for all those working in tropical diseases, public health and virology. Praise from the reviews: "The book provides an excellent summary of dengue/flavivirus research and is important for individuals and institutions interested in emerging infectious diseases." MICROBIOLOGY TODAY
Continued geographic expansion of dengue viruses and their mosquito vectors has seen the magnitude and frequency of epidemic dengue/dengue hemorrhagic fever (DF/DHF) increase dramatically. Recent exciting research on dengue has resulted in major advances in our understanding of all aspects of the biology of these viruses, and this updated second edition brings together leading research and clinical scientists to review dengue virus biology, epidemiology, entomology, therapeutics, vaccinology and clinical management.
Discusses how to fight Ebola, SARS Corona, and other known or emerging human viruses by building on the successes in antiviral therapy of the past decades Written by leading medicinal chemists from academia and industry, this book discusses the entire field of antiviral drug discovery and development from a medicinal chemistry perspective, focusing on antiviral drugs, targets, and viral disease mechanisms. It provides an outlook on emerging pathogens such as Ebola, Zika, West Nile, Lassa, and includes a chapter on SARS Coronoavirus-2 causing the present pandemic. New Drug Development for Known and Emerging Viruses describes the discovery and development process for antiviral agents for different classes of viruses and targets based on the experiences from the nine human viruses for which approved drugs are on the market (HIV, HCV, Influenza, RSV, HBV, HPV, HCMV, HSV, and VZV). It covers the properties and potential of 20 classes of currently approved antivirals, including combination drugs, and looks at novel antiviral strategies against emerging viruses. Covers the entire field of antiviral drug discovery and development Addresses the need for antiviral drugs to combat major health threats such as Ebola, Zika, West Nile, and SARS Coronavirus-2 Summarizes the successes of the past 15 years in developing ground-breaking medicines against 9 major human viruses, both from the medicinal chemistry and the pharmacological angle Discusses practical and strategic challenges in the drug discovery and development process, including screening technologies, latency, and toxicity issues New Developments in Antiviral Drugs is an important book for medicinal chemists, pharmaceutical chemists, virologists, and epidemiologists, and will be of great interest to those in the ;pharmaceutical industry and public health agencies.
This contributed volume contains 25 chapters from leading international scientists working on dengue and Zika viruses, who came together in Praia do Tofo in Mozambique to discuss the latest developments in the fields of epidemiology, pathogenesis, structural virology, immunology, antiviral drug discovery and development, vaccine efficacy, and mosquito control programs. The meeting venue offered an opportunity to discuss current research on these flaviviruses in an idyllic setting, and also to develop first-hand appreciation of the issues in infectious diseases facing developing countries and of the research gaps in Africa. For readers, who should include basic and clinical researchers in the field and public health professionals, the chapters are organized to provide a comprehensive overview of the various topics in current dengue and Zika virus research. A unique feature of the proceedings of this meeting is the inclusion of the discussions that took place following presentations. These have been transcribed and appended to the end of the relevant chapters, and they form the “salt in the soup” of this book.
Over 50% of known flaviviruses have been associated with human disease. The Flavivirus genus constitutes some of the most serious human pathogens including Japanese encephalitis, dengue and yellow fever. Flaviviruses are known for their complex life cycles and epidemic spread, and are considered a globally-emergent viral threat. Detection, Diagnosis and Vaccine Development, the third volume of The Flaviviruses details the current status of technologies for detection and differentiation of these viruses, their use in surveillance and outbreak investigation, and also reviews the latest clinical research. - Comprehensive approach to the scientific disciplines needed to unravle the complexities of virus-host interactions - Descibes the technologies that have contributed to our current knowledge about the Flaviviruses - Identifies the major problems faced in understanding the virus-host interactins that result in disease - An exhaustive compendium of current and past knowledge on the Flavivirus family
For over 70 years, dengue fever has challenged health systems in every region of the World. It has evolved from a benign febrile illness from the tropics to a major concern in urban settlements, overwhelming health infrastructure with large outbreaks, as it continues to teach us important lessons with its complexities. This book intends to review the latest updates on dengue fever, the tools available for its study and control, and promising technologies currently in the pipeline. With this work, the editors wish to provide students with an updated reference text on the basics of this disease as well as researchers and academics, with a useful document to understand the current outlook and the perspectives for the future.
Dengue and its potentially fatal forms, dengue henorrhagic fever and dengue shock syndrome, once more threaten much of the Americas. In the 1980s the vector control programmes fell victim to the cutbacks in public health expenditure and their responses to dengue outbreaks tended to be a little too late. These guidelines have risen to the challenge by incorporating all aspects of the prevention and control of the disease and its vectors. In addition, because dengue is primarily a problem of domestic sanitation and households can combat the problem inexpensively. The guidelines enmphasize ways to transfer responsibility for dengue control and prevention to the community."
